Metzger M J，et al.Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams[J].Cell，2015，161（2）：255-263.
Zhou C.Lung cancer molecular epidemiology in China：recent trends[J].Transl Lung Cancer Res.2014，3（5）：270-279.
Yock T I，et al.Quality of life outcomes in proton and photon treated pediatric brain tumor survivors[J].Radiother Oncol，2014，113（1）：89-94.
Yadav M，et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature，2014，515（7528）：572-576.
Warren G W，et al.The 2014 Surgeon General’s report：“The health consequences of smoking — 50 years of progress”：a paradigm shift in cancer care[J].Cancer，2014，120（13）：1914-1916.
Solomon B J，et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med，2014，371（23）：2167-2177.
Snyder A，et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].N Engl J Med，2014，371（23）：2189-2199.
Shi Y，et al.A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology（PIONEER） [J].J Thorac Oncol，2014，9（2）：154-162.
Shen L，Ji H F.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].N Engl J Med，2014，370（26）：2537.
Shaw A T，Engelman J A.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].N Engl J Med，2014，370（26）：2537-2539.
Sayin V I，et al.Antioxidants accelerate lung cancer progression in mice[J].Sci Transl Med，2014，6（221）：221ra15.
Mitin T A，Zietman L.Promise and pitfalls of heavy-particle therapy[J].J Clin Oncol，2014，32（26）：2855-2863.
Mendenhall N P，et al.Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer[J].Int J Radiat Oncol Biol Phys，2014，88（3）：596-602.
Maude S L，et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med，2014，371（16）：1507-1517.
Lin Y，et al.Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers[J].Proc Natl Acad Sci U S A，2014，111（42）：E4504-4512.
Herbst R S，et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature，2014，515（7528）：563-567.
Gubin M M，et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature，2014，515（7528）：577-581.
Gragert L，et al.HLA match likelihoods for hematopoietic stem-cell grafts in the U.S.registry[J].N Engl J Med，2014，371（4）：339-348.
Bonadies D C，et al.Adverse events in cancer genetic testing：the third case series[J].Cancer J，2014，20（4）：246-53.
Retraction notice to “Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize”Food Chem Toxicol，2014，63：244.
Wolchok J D，et al.Nivolumab plus ipilimumab in advanced melanoma[J].N Engl J Med，2013，369（2）：122-133.
Watson I R，et al.Emerging patterns of somatic mutations in cancer[J].Nat Rev Genet，2013，14（10）：703-718.
Vacchelli E，et al.Trial watch：Oncolytic viruses for cancer therapy[J].Oncoimmunology，2013，2（6）：e24612.
Shi Y，et al.Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer（ICOGEN）：a randomised，double-blind phase 3 non-inferiority trial[J].Lancet Oncol，2013，14（10）：953-961.
Nixon I J，et al.The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer，based on Memorial Sloan-Kettering Cancer Center risk group stratification[J].Thyroid，2013，23（6）：683-694.
Li Y，et al.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer[J].PLoS One，2013，8（1）：e52093.
Lawrence M S，et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature，2013，499（7457）：214-218.
Hamid O，et al.Safety and tumor responses with lambrolizumab（anti-PD-1） in melanoma[J].N Engl J Med，2013，369（2）：134-144.
Chung C S，et al.Incidence of second malignancies among patients treated with proton versus photon radiation[J].Int J Radiat Oncol Biol Phys，2013，87（1）：46-52.
Arcila M E，et al.EGFR exon 20 insertion mutations in lung adenocarcinomas：prevalence，molecular heterogeneity，and clinicopathologic characteristics[J].Mol Cancer Ther，2013，12（2）：220-229.
Wang Y C，et al.Comparison of Cancer Incidence between China and the USA[J].Cancer Biol Med，2012，9（2）：128-132.
Topalian S L，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med，2012，366（26）：2443-2454.
Seralini G E，et al.Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize[J].Food Chem Toxicol，2012，50（11）：4221-4231.
Lim S S，et al.A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet，2012，380（9859）：2224-2260.
Govindan R，et al.Genomic landscape of non-small cell lung cancer in smokers and never-smokers[J].Cell，2012，150（6）：1121-1134.
An S J，et al.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status[J].PLoS One，2012，7（6）：e40109.
Zava T T，Zava D T.Assessment of Japanese iodine intake based on seaweed consumption in Japan：A literature-based analysis[J].Thyroid Res，2011，4：14.
Wagle N，et al.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling[J].J Clin Oncol，2011，29（22）：3085-3096.
Sequist L V，et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med，2011，3（75）：75ra26.
Ramaekers B L，et al.Systematic review and meta-analysis of radiotherapy in various head and neck cancers：comparing photons，carbon-ions and protons[J].Cancer Treat Rev，2011，37（3）：185-201.
Pederson T，Mukherjee S.The Emperor of All Maladies A Biography of Cancer[J].Science，2011，332（6028）：423-423.
Moeller B J，et al.Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy[J].Radiat Oncol，2011，6：58.
Miller L H，Su X.Artemisinin：discovery from the Chinese herbal garden[J].Cell，2011，146（6）：855-858.
Domchek S M，et al.Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality[J].JAMA，2010，304（9）：967-975.
Sawka A M，et al.Second primary malignancy risk after radioactive iodine treatment for thyroid cancer：a systematic review and meta-analysis[J].Thyroid，2009，19（5）：451-457.
Little M P.Cancer and non-cancer effects in Japanese atomic bomb survivors[J].J Radiol Prot，2009，29（2A）：A43-59.
Lawenda B D，et al.Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy？[J].J Natl Cancer Inst，2008，100（11）：773-783.
Dishop M K，Kuruvilla S.Primary and metastatic lung tumors in the pediatric population：a review and 25-year experience at a large children’s hospital[J].Arch Pathol Lab Med，2008，132（7）：1079-1103.
Ballen K K，et al.Collection and preservation of cord blood for personal use[J].Biol Blood Marrow Transplant，2008，14（3）：356-363.
Schoder H，Gonen M.Screening for cancer with PET and PET/CT：potential and limitations[J].J Nucl Med，2007，48 Suppl 1：4S-18S.
McLaughlin J R，et al.Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations：a case-control study[J].Lancet Oncol，2007，8（1）：26-34.
Kelly E，Russell S J.History of oncolytic viruses：genesis to genetic engineering[J].Mol Ther，2007，15（4）：651-659.
Eapen M，et al.Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia：a comparison study[J].Lancet，2007，369（9577）：1947-1954.
Bjelakovic G，et al.Mortality in randomized trials of antioxidant supplements for primary and secondary prevention：systematic review and meta-analysis[J].JAMA，2007，297（8）：842-857.
Pearse A M，Swift K.Allograft theory：transmission of devil facial-tumour disease[J].Nature，2006，439（7076）：549.
Murgia C，et al.Clonal origin and evolution of a transmissible cancer[J].Cell，2006，126（3）：477-487.
Garber K.China approves world’s first oncolytic virus therapy for cancer treatment[J].J Natl Cancer Inst，2006，98（5）：298-300.
Druker B J，et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[J].N Engl J Med，2006，355（23）：2408-2417.
Lundkvist J，et al.Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma[J].Cancer，2005，103（4）：793-801.
Ludwig J A，Weinstein J N.Biomarkers in cancer staging，prognosis and treatment selection[J].Nat Rev Cancer，2005，5（11）：845-856.
van der Zee，J.Heating the patient：a promising approach？[J].Ann Oncol，2002，13（8）：1173-1184.
Srivastava S R.Gopal-Srivastava，Biomarkers in cancer screening：a public health perspective[J].J Nutr，2002，132（8 Suppl）：2471S-2475S.
Miralbell R，et al.Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors[J].Int J Radiat Oncol Biol Phys，2002，54（3）：824-829.
Nishimura H，et al.Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J].Immunity，1999，11（2）：141-151.
Patterson R E，et al.Vitamin supplements and cancer risk：the epidemiologic evidence[J].Cancer Causes Control，1997，8（5）：786-802.
Jha P，et al.The antioxidant vitamins and cardiovascular disease.A critical review of epidemiologic and clinical trial data[J].Ann Intern Med，1995，123（11）：860-872.
Ferrara J L，Abhyankar S，Gilliland D G.Cytokine storm of graft-versus-host disease：a critical effector role for interleukin-1[J].Transplant Proc，1993，25（1 Pt 2）：1216-1217.
Newcomb P A，Carbone P P.The health consequences of smoking.Cance[J]r.Med Clin North Am，1992，76（2）：305-331.
Martuza R L，et al.Experimental therapy of human glioma by means of a genetically engineered virus mutant[J].Science，1991，252（5007）：854-856.
Rosenberg S A，et al.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer[J].N Engl J Med，1985，313（23）：1485-1492.
Morahan P S，et al.Paradoxical effects of immunopotentiators on tumors and tumor viruses[J].J Infect Dis，1976，133 Suppl：A249-255.
Yohn D S，et al.Oncolytic potentials of nonhuman viruses for human cancer.Ⅱ.Effects of five viruses on heterotransplantable human tumors[J].J Natl Cancer Inst，1968，41（2）：523-529.
Moore A E.Effects of viruses on tumors[J].Annu Rev Microbiol，1954，8：393-410.
Southam C M，Moore A E.Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus[J].Cancer，1952，5（5）：1025-1034.
本书评论